Zhitong Finance App News, Zhixiang Jintai (688443.SH) issued an announcement. Recently, the company's product telicibimab injection (GR1802 injection) was included in the list of priority review varieties by the Drug Evaluation Center of the China Drug Administration.

Teliximab injection (GR1802 injection) is a recombinant all-human anti-IL-4Rα monoclonal antibody independently developed by the company. The target of action is IL-4Rα. Telicibimab injection can specifically bind human IL-4Rα on the cell surface, block the binding of IL-4, IL-13 and IL-4Rα, inhibit downstream STAT6 phosphorylation, and inhibit CD23 upregulation, thereby inhibiting the TH2 inflammatory response mediated by IL-4 or IL-13.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.